GOSS
Price
$3.44
Change
+$0.15 (+4.56%)
Updated
Dec 24 closing price
Capitalization
796.21M
78 days until earnings call
Intraday BUY SELL Signals
RVPH
Price
$0.28
Change
-$0.04 (-12.50%)
Updated
Dec 24 closing price
Capitalization
32.48M
88 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GOSS vs RVPH

Header iconGOSS vs RVPH Comparison
Open Charts GOSS vs RVPHBanner chart's image
Gossamer Bio
Price$3.44
Change+$0.15 (+4.56%)
Volume$3.25M
Capitalization796.21M
Reviva Pharmaceuticals Holdings
Price$0.28
Change-$0.04 (-12.50%)
Volume$14.55M
Capitalization32.48M
GOSS vs RVPH Comparison Chart in %
GOSS
Daily Signal:
Gain/Loss:
RVPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GOSS vs. RVPH commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and RVPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (GOSS: $3.44 vs. RVPH: $0.28)
Brand notoriety: GOSS and RVPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 93% vs. RVPH: 203%
Market capitalization -- GOSS: $796.21M vs. RVPH: $32.48M
GOSS [@Biotechnology] is valued at $796.21M. RVPH’s [@Biotechnology] market capitalization is $32.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileRVPH’s FA Score has 1 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • RVPH’s FA Score: 1 green, 4 red.
According to our system of comparison, GOSS is a better buy in the long-term than RVPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 3 TA indicator(s) are bullish while RVPH’s TA Score has 5 bullish TA indicator(s).

  • GOSS’s TA Score: 3 bullish, 5 bearish.
  • RVPH’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RVPH is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а -3.64% price change this week, while RVPH (@Biotechnology) price change was -54.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

GOSS is expected to report earnings on Mar 13, 2026.

RVPH is expected to report earnings on Mar 23, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GOSS($796M) has a higher market cap than RVPH($32.5M). GOSS YTD gains are higher at: 280.279 vs. RVPH (-84.641). RVPH has higher annual earnings (EBITDA): -22.71M vs. GOSS (-145.74M). GOSS has more cash in the bank: 180M vs. RVPH (13.2M). RVPH has less debt than GOSS: RVPH (113K) vs GOSS (203M). GOSS has higher revenues than RVPH: GOSS (44.1M) vs RVPH (0).
GOSSRVPHGOSS / RVPH
Capitalization796M32.5M2,449%
EBITDA-145.74M-22.71M642%
Gain YTD280.279-84.641-331%
P/E RatioN/AN/A-
Revenue44.1M0-
Total Cash180M13.2M1,364%
Total Debt203M113K179,646%
FUNDAMENTALS RATINGS
GOSS vs RVPH: Fundamental Ratings
GOSS
RVPH
OUTLOOK RATING
1..100
2558
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3565
P/E GROWTH RATING
1..100
10010
SEASONALITY SCORE
1..100
5010

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for RVPH (92) in the null industry. This means that GOSS’s stock grew somewhat faster than RVPH’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RVPH (100) in the null industry. This means that GOSS’s stock grew similarly to RVPH’s over the last 12 months.

GOSS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as RVPH (100) in the null industry. This means that GOSS’s stock grew similarly to RVPH’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as RVPH (65) in the null industry. This means that GOSS’s stock grew similarly to RVPH’s over the last 12 months.

RVPH's P/E Growth Rating (10) in the null industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that RVPH’s stock grew significantly faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSRVPH
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signal:
Gain/Loss:
RVPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFGEX10.490.05
+0.48%
DFA Global Real Estate Securities Port
OBSOX29.910.07
+0.23%
Oberweis Small-Cap Opportunities
DEQYX12.710.02
+0.16%
BNY Mellon Global Equity Income - Y
BIGTX16.130.02
+0.12%
The Texas I
CHDVX13.16N/A
N/A
Cullen High Dividend Equity I

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
+4.72%
LITS - GOSS
46%
Loosely correlated
+1.46%
ABEO - GOSS
41%
Loosely correlated
+2.08%
APVO - GOSS
41%
Loosely correlated
-8.81%
XNCR - GOSS
40%
Loosely correlated
-0.13%
NUVL - GOSS
39%
Loosely correlated
+0.89%
More

RVPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, RVPH has been loosely correlated with ALT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RVPH jumps, then ALT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVPH
1D Price
Change %
RVPH100%
-13.48%
ALT - RVPH
50%
Loosely correlated
-0.50%
INM - RVPH
29%
Poorly correlated
-2.38%
GOSS - RVPH
29%
Poorly correlated
+4.72%
INDP - RVPH
29%
Poorly correlated
+35.90%
ABOS - RVPH
27%
Poorly correlated
-0.46%
More